Bristol-Myers Squibb's key drugs are losing patent protection, while more recently launched drugs are struggling to meet peak revenue expectations. Learn more about BMY stock here.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

The FDA's priority review for Opdivo with AVD targets first-line treatment for stage 3 or 4 cHL in patients aged 12 and older. The phase 3 SWOG S1826 study supports the review, focusing on progression ...

Bristol Myers BMY has a broad oncology portfolio, which includes blockbuster immuno-oncology drugs, Opdivo, Opdivo Qvantig and Yervoy, among others. Among these, Opdivo (nivolumab) is the top revenue ...

Cohen & Steers Limited Duration Preferred and Income Fund remains a hold, reflecting its sensitivity to interest rates and concentrated banking sector exposure. LDP trades at a 4.3% discount to NAV, ...

The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.

World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Investopedia / Arif Qazi, Ellen Lindner, Joules Garcia, Mira Norian, and Yurle ...

The CEO of a charter school network based in New York City, Success Academy, argued that the system was failing students shortly after New York released its report card for grades 3–8. "The children ...